科倫藥業(002422.SZ):子公司擬設疆寧生物 大力開發和拓展綠色生物農藥、動物保健等市場
格隆匯 9 月 25日丨科倫藥業(002422.SZ)公佈,公司第六屆董事會第三十三次會議決議,審議通過了《關於對外投資設立子公司的議案》。
同意公司控股子公司川寧生物根據經營規劃和業務發展的需要,在伊犁哈薩克自治州鞏留縣設立伊犁疆寧生物技術有限公司(暫定名,以工商登記核准名稱為準,“疆寧生物”),註冊資本1億元,川寧生物持股100%。
基於川寧生物擁有大體量的生物發酵平台和國際領先的環保技術,疆寧生物將利用豐富的資源優勢和區位優勢,大力開發和拓展綠色生物農藥、動物保健等市場,進一步調整公司產品結構,以滿足不斷增長的市場需求,有利於川寧生物由資源要素驅動向技術創新驅動的轉變,有利於川寧生物進行產品品類的擴張,為川寧生物帶來新的利潤增長點,從而提高川寧生物在行業內的競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.